title: Changes in bone turnover during tibolone treatment.
abstract: OBJECTIVE
  An open study was carried out to evaluate changes in bone remodeling markers such as N-telopeptide (NTx), tartrate-resistant acid phosphatase (TRAP), total alkaline phosphatase (TAP), and bone alkaline phosphatase (BAP) during a 1-year continuous tibolone treatment in postmenopausal women.
  
  
  METHODS
  Thirty-six postmenopausal women were recruited for receiving tibolone 2.5 mg per day for 1 year. Densitometry and determination of biochemical markers of bone metabolism in serum and urine were performed at 1, 3, 6, and 12 months.
  
  
  RESULTS
  Comparing baseline with 12 month's values, BAP and all resorption markers decreased significantly. NTx began to decrease since the initiation of the treatment (baseline: 74.4 +/- 5.3; 1 month: 57.5 +/- 4.2; 12 months: 36.6 +/- 2.8). BAP increased at the first month (baseline: 37.3 +/- 2.1; 1 month: 42.6 +/- 3.0) but diminished in the following months (12 months: 23.1 +/- 1.5). TAP started to decrease significantly only after 6 months of treatment (baseline: 37.3 +/- 2.1; 12 months: 31.4 +/- 2.3) and TRAP after 3 months (baseline: 9.8 +/- 0.4; 6 months: 9.1 +/- 0.5; 12 months: 8.2 +/- 0.4). Normal bone mineral density at distal and ultradistal forearm was maintained during the 1-year treatment (baseline: 0.42 +/- 0.01; 12 months: 0.42 +/- 0.01 and baseline: 0.33 +/- 0.01; 12 months: 0.33 +/- 0.01, respectively).
  
  
  CONCLUSIONS
  The use of tibolone 2.5 mg per day diminished progressively and significantly bone resorption and formation markers during 1-year treatment period.
authors.affiliation: UNILIME, Universidad de Carabobo, Hospital Universitario Dr. Angel Larralde, IVSS, Valencia, Venezuela. griera@net-uno.net
authors.forename: Gregorio
authors.initials: G
authors.lastname: Riera-Espinoza
authors.forename: Jenny
authors.initials: J
authors.lastname: Ramos
authors.forename: Rosalía
authors.initials: R
authors.lastname: Carvajal
authors.forename: Emma
authors.initials: E
authors.lastname: Belzares
authors.forename: Guadalupe
authors.initials: G
authors.lastname: Stanbury
authors.forename: Rosa
authors.initials: R
authors.lastname: Farías
authors.forename: Inés
authors.initials: I
authors.lastname: Valderrama
authors.forename: Kelia
authors.initials: K
authors.lastname: Alvarez
authors.forename: Gregorio
authors.initials: G
authors.lastname: Riera-González
mesh_terms: D000135:Acid Phosphatase / Q000032:analysis; D000469:Alkaline Phosphatase / Q000032:analysis; D045930:Anabolic Agents / Q000627:therapeutic use*; D015415:Biomarkers / Q000032:analysis; D015519:Bone Density / Q000187:drug effects / Q000502:physiology; D016723:Bone Remodeling / Q000187:drug effects*; D003094:Collagen / Q000032:analysis; D024042:Collagen Type I; D004334:Drug Administration Schedule; D005260:Female; D005542:Forearm; D006801:Humans; D007527:Isoenzymes / Q000032:analysis; D008875:Middle Aged; D009652:Norpregnenes / Q000627:therapeutic use*; D015663:Osteoporosis, Postmenopausal / Q000517:prevention & control*; D010455:Peptides / Q000032:analysis; D000071681:Tartrate-Resistant Acid Phosphatase
chemical_list: D045930:Anabolic Agents; D015415:Biomarkers; D024042:Collagen Type I; D007527:Isoenzymes; D009652:Norpregnenes; D010455:Peptides; C052929:collagen type I trimeric cross-linked peptide; D003094:Collagen; D000469:Alkaline Phosphatase; D000135:Acid Phosphatase; D000071681:Tartrate-Resistant Acid Phosphatase; C027385:tibolone